Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Leases (2023 - 2025)

China SXT Pharmaceuticals (SXTC) has 3 years of Current Leases data on record, last reported at $61229.0 in Q1 2025.

  • For Q1 2025, Current Leases rose 5.01% year-over-year to $61229.0; the TTM value through Mar 2025 reached $61229.0, up 5.01%, while the annual FY2025 figure was $61229.0, 5.01% up from the prior year.
  • Current Leases reached $61229.0 in Q1 2025 per SXTC's latest filing, up from $58310.0 in the prior quarter.
  • Across five years, Current Leases topped out at $61229.0 in Q1 2025 and bottomed at $58089.0 in Q1 2023.
  • Average Current Leases over 3 years is $59209.3, with a median of $58310.0 recorded in 2024.
  • Peak YoY movement for Current Leases: grew 0.38% in 2024, then rose 5.01% in 2025.
  • A 3-year view of Current Leases shows it stood at $58089.0 in 2023, then grew by 0.38% to $58310.0 in 2024, then grew by 5.01% to $61229.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $61229.0 in Q1 2025, $58310.0 in Q1 2024, and $58089.0 in Q1 2023.